Inactive Instrument

Press Releases Pharmagest Interactive SA Swiss Exchange

Equities

End-of-day quote Swiss Exchange Other stock markets
- ^EUR	-

08/05	Equasens: sales down 5% in Q1	CF
30/04	Equasens Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Equasens: Q1 2024 revenue	07/05	GL
Equasens: 2023 Annual Results	29/03	GL
Equasens: 2023 revenue: €219.7m, +2.6%	06/02	GL
Equasens: Acquisition of a majority stake in DIGIPHARMACIE	02/01	GL
Equasens: Changes in the Equasens Group Executive Committee	27/12	GL
EQUASENS: Acquisition of the German company ADV and creation of PHARMAGEST Germany	23/11	GL
Equasens: Q3 2023 revenue	09/11	GL
Equasens : SFAF Presentation – H1 2023 results	04/23/04	PU
EQUASENS: H1 2023 Results	29/23/29	GL
EQUASENS GROUP: H1 2023 revenue: up 9% to €112.62m	03/23/03	GL
Equasens : Results of the votes on the resolutions submitted to the Ordinary Annual Shareholders’ Meeting of 29 June 2023	05/23/05	PU
EQUASENS: results of the votes on the resolutions submitted to the ordinary annual shareholders' meeting of 29 june 2023	05/23/05	GL
EQUASENS: ANNUAL ORDINARY GENERAL MEETING - MEETING NOTICE - ON-LINE AVAILABILITY OF MEETING MATERIALS	09/23/09	GL
Equasens : Meeting Notice (AGOA 29.06.2023)	09/23/09	PU
Equasens : Preliminary Notice (AGOA 29.06.2023)	06/23/06	PU
EQUASENS: Q1 2023 revenue: +13.96% to €56.25m	11/23/11	GL
EQUASENS: 2022 Net Profit: +18.35% to €48.70m	24/23/24	GL
EQUASENS: FY 2022 revenue: +10.88% to €214.07m	03/23/03	GL
EQUASENS: H2 2022 HALF-YEAR REPORT ON THE LIQUIDITY AGREEMENT WITH GILBERT DUPONT	20/23/20	GL
EQUASENS: Appointment of Frédérique SCHMIDT as the Group’s Chief Administrative and Financial Officer	19/23/19	GL

No results for this search